文章核心观点 - Verve Therapeutics股价上一交易日上涨18.7%，或因投资者对其临床阶段产品线潜力乐观，公司预计季度亏损但营收增长，需关注后续走势；Karyopharm Therapeutics上一交易日股价下跌3%，EPS预期有变化 [1][2][3][4] Verve Therapeutics股价表现 - 上一交易日股价上涨18.7%，收于7.80美元，成交量高于平常，过去四周累计上涨13.9% [1] Verve Therapeutics业务进展 - 公司正在早期研究中开发VERVE - 102用于两种适应症，Ib期Heart - 2研究初步数据预计2025年第二季度公布；还有VERVE - 201和VERVE - 301两个早期管线候选药物 [2] Verve Therapeutics财务预期 - 即将公布的报告预计季度每股亏损0.72美元，同比变化-4.4%；营收预计687万美元，同比增长33.7% [3] Verve Therapeutics盈利预测 - 过去30天该季度的共识每股收益预期保持不变，股票目前Zacks排名为3（持有） [4] Karyopharm Therapeutics股价表现 - 上一交易日股价下跌3%，收于0.67美元，过去一个月回报率为15.4% [4] Karyopharm Therapeutics盈利预测 - 即将公布报告的共识每股收益预期过去一个月变化-27.5%至-0.26美元，与去年同期相比变化+27.8%，目前Zacks排名为4（卖出） [5]

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development candidate targeting the LPA gene; Verve to receive an associated milestone payment from Eli Lilly Well-capitalized with cash runway extending into mid-2027 Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. ET/11:15 a.m. PT BOSTON, Ja ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development candidate targeting the LPA gene; Verve to receive an associated milestone payment from Eli Lilly Well-capitalized with cash runway extending into mid-2027 Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. ET/11:15 a.m. PT BOSTON, Ja ...

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 3 ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.71%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.68 per share when it actually produced a loss of $0.59, delivering a surprise of 13.24%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4 ...

Exhibit 99.1 Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3; Regulatory clearances in Australia, Canada, and the U.K. Cash, cash equivalents, and marketable securities of $539.9 million; cash runway through 2 ...

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV).Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=109388&from=4CLASS PERIOD: Augus ...

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of a ...

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.So what: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of po ...